In This Section

AACR Annual Meeting 2026 Press Program

The American Association for Cancer Research is hosting its 117th Annual Meeting from April 17-22, 2026, at the San Diego Convention Center in San Diego, California. 

The AACR Annual Meeting is the focal point of the cancer research community. This year’s meeting, to be held April 17-22, will offer approximately 22,000 researchers, physicians, and advocates from around the world an opportunity to share and discuss the latest advances in basic, translational, and clinical cancer research and cancer-related population sciences.

To help reporters plan coverage of the meeting, the AACR prepared the following press program.

PRESS CONFERENCE 1

AACR Annual Meeting Clinical Trials Committee Cochair Jayesh Desai, MD, Peter MacCallum Cancer Centre, moderated the first press conference.

Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer

  • Presented by Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Yonsei University College of Medicine

Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer

  • Presented by Jonathan W. Riess, MD, UC Davis Comprehensive Cancer Center

New Antibody-drug Conjugate Shows Clinical Benefit for Advanced Platinum-resistant Ovarian Cancer

  • Presented by Tao Zhu, MD, Zhejiang Cancer Hospital
View the press conference

PRESS CONFERENCE 2

AACR Annual Meeting Clinical Trials Committee Cochair Ecaterina E. Dumbrava, MD, moderated the second press conference.

BCMA-directed CAR T-cell Therapy May Be Effective Against High-risk Smoldering Multiple Myeloma

  • Presented by Omar Nadeem, MD, Dana-Farber Cancer Institute, Harvard Medical School.

A Machine Learning Model that Uses DNA Methylation Patterns May Help Identify the Origin of Cancers of Unknown Primary

  • Presented by Marco A. De Velasco, PhD, Kindai University in Japan

A Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy in Lung Cancer Patients

  • Presented by Rukhmini Bandyopadhyay, PhD, The University of Texas MD Anderson Cancer Center
view the press conference

PRESS CONFERENCE 3

AACR Annual Meeting Clinical Trials Committee Cochair Ecaterina E. Dumbrava, MD, moderated the second press conference.

Early Myocarditis Onset After Immunotherapy May Predict Treatment-related Fatality

  • Presented by Hassan M. Abushukair, MD, Oklahoma University Stephenson Cancer Center

Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions

  • Presented by Moran Amit, MD, PhD, The University of Texas MD Anderson Cancer Center

Exposure to Wildfire Smoke May Be Linked To Increased Risk of Developing Several Cancers

  • Presented by Shuguang Leng, MBBS, PhD, The University of New Mexico Comprehensive Cancer Center
View the press conference